Corcept Therapeutics Inc (CORT) stock
CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30530% above fair value
$69.22−3.72 (-5.10%)
Close on Nov 16, 2026Market cap $7.48BP/E 164.8Yield –
Corcept Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Corcept Therapeutics's price to sales ratio was 10.4× on Nov 11, 2026, against 12.8× a year earlier. Over the last 5 years it ranged from 5.0× to 17.8×, with a median of 7.6×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 10.4× | +4.7 |
| 2025 | Dec 31, 2025 | 5.6× | −3.3 |
| 2024 | Dec 31, 2024 | 8.9× | +0.8 |
| 2023 | Dec 29, 2023 | 8.2× | +2.2 |
| 2022 | Dec 30, 2022 | 6.0× | −1.1 |
| 2021 | Dec 31, 2021 | 7.1× | −1.9 |
| 2020 | Dec 31, 2020 | 9.1× | +3.8 |
| 2019 | Dec 31, 2019 | 5.2× | −1.9 |
| 2018 | Dec 31, 2018 | 7.2× | −8.7 |
| 2017 | Dec 29, 2017 | 15.9× | +4.8 |
| 2016 | Dec 30, 2016 | 11.1× | −1.1 |
| 2015 | Dec 31, 2015 | 12.2× | −1.8 |
| 2014 | Dec 31, 2014 | 14.0× | −28.0 |
| 2013 | Dec 31, 2013 | 42.1× | – |
See a number that looks wrong?